demonstrated that, in EGFR mutant ALK-positive NSCLC, which is nonresponsive to PD-1 inhibitor, the upregulation of CD73 via the ERK-Jun pathway amplifies CD73 at the genomic level (97). This evidence concerns the gene NT5E and non-small cell lung carcinoma.